Immunovia AB (OSTO:IMMNOV) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 27, 2026)


OSTO:IMMNOV Immunovia AB OSTO:IMMNOV
43 GF Score
Price kr0.19
GF Value kr0.07
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Immunovia AB Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Immunovia AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

OSTO:IMMNOV vs TMO, DHR, IDXX: Margin of Safety % (DCF FCF Based) Comparison

For the Diagnostics & Research subindustry, Immunovia AB's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunovia AB Margin of Safety % (DCF FCF Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Immunovia AB's Margin of Safety % (DCF FCF Based) falls into.


OSTO:IMMNOV
43GF Score
Immunovia AB OSTO:IMMNOV
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immunovia AB (OSTO:IMMNOV) Overvalued in 2026?

Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued. The current stock price of kr0.19 is trading 170% above its estimated GF Value™ of kr0.07. GuruFocus considers Immunovia AB to be Significantly Overvalued.

Key valuation signals for OSTO:IMMNOV:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: kr0.07 vs. price of kr0.19 (170% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the OSTO:IMMNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunovia AB Business Description

Other Exchanges 0G8X:UK
Address Scheelevagen 8, Medicon Village, Lund, SWE, 223 63
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score

Get the complete analysis for OSTO:IMMNOV

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.19
Price
kr0.07
GF Value